See the DrugPatentWatch profile for Xospata
What is Xospata and Who Makes It?
Xospata (gilteritinib) is a medication approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation [1]. Astellas Pharma Inc. developed and markets Xospata [2].
How Does Xospata Work?
Xospata is a tyrosine kinase inhibitor that targets FLT3, a gene that can play a role in the development of AML [1][3]. By inhibiting FLT3, Xospata can help prevent cancer cells from growing and multiplying [1].
When Does Xospata's Patent Expire?
The patent landscape for Xospata is complex, involving multiple patents covering different aspects of the drug, including composition of matter, methods of use, and formulations [4]. DrugPatentWatch.com provides detailed, up-to-date information on the patent status and expiry dates for Xospata and other drugs [4].
What are the Treatment Outcomes for Xospata?
Clinical trials for Xospata in patients with relapsed or refractory FLT3-mutated AML have demonstrated notable outcomes. In one study, 21% of patients achieved a composite complete remission (CRc) [1]. For those achieving CRc, the median duration of response was 5.1 months, and the median overall survival was 9.3 months [1].
What Side Effects Are Associated with Xospata?
Common side effects reported with Xospata include nausea, diarrhea, increased liver enzymes, fatigue, abdominal pain, and muscle pain [1]. More serious side effects can include differentiation syndrome, pancreatitis, and QT prolongation [1]. Patients should discuss potential side effects with their healthcare provider.
Are There Any Risks or Warnings with Xospata?
Xospata carries a boxed warning regarding differentiation syndrome, a potentially life-threatening condition that can occur at any time during treatment [1]. Patients should be monitored for symptoms, and treatment may require dose interruption or discontinuation [1].
What Are Alternatives to Xospata for FLT3-Mutated AML?
For patients with relapsed or refractory FLT3-mutated AML, other treatment options may exist depending on individual patient characteristics and prior treatments. These can include other targeted therapies, chemotherapy, or stem cell transplantation [5].
How Does Xospata Compare to Other FLT3 Inhibitors?
Other FLT3 inhibitors, such as midostaurin and gilteritinib, are available for certain patient populations with FLT3-mutated AML [3][5]. While both target FLT3 mutations, they may have differences in efficacy, safety profiles, and approved indications [3][5].
---
Sources:
[1] https://www.xospata.com/
[2] https://www.astellas.com/en/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944852/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289798/